Merck

FDA approves Merck’s Recarbrio

FDA approves Merck’s Recarbrio

KENILWORTH, N.J. — Merck announced Friday that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms.

IAVI and Merck collaborate to develop vaccine against SARS-CoV-2

IAVI and Merck collaborate to develop vaccine against SARS-CoV-2

KENILWORTH, N.J. — Merck  and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, today announced a new collaboration to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis

Merck to acquire Themis

Merck to acquire Themis

KENILWORTH, N.J.— Merck  announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a

Merck announces appointment of Organon & Co. CFO and CIO

Merck announces appointment of Organon & Co. CFO and CIO

KENILWORTH, N.J. — Merck, known as MSD outside the United States and Canada, announced the appointment of Matthew Walsh and Rachel Stahler as chief financial officer and chief information officer, respectively, for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses. In his new role at Organon, Walsh will

Merck and ISB team to define molecular mechanisms of SARS-CoV-2 infection

Merck and ISB team to define molecular mechanisms of SARS-CoV-2 infection

KENILWORTH, N.J. — Merck and the Institute for Systems Biology (ISB), announced on Monday a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of

Merck announces launch of Ontruzant

Merck announces launch of Ontruzant

KENILWORTH, N.J. — Merck announced the U.S. launch of Ontruzant (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin. Ontruzant is available in both 150 mg single-dose vials and 420 mg multiple-dose vials. Ontruzant will be introduced in the U.S. at a list price (wholesaler acquisition cost) of approximately $1,325 for the 150 mg

Merck to buy ArQule, advancing leadership in oncology

Merck to buy ArQule, advancing leadership in oncology

KENILWORTH, N.J. — Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development

Walmart working with IBM, Merck on new Rx program

Walmart working with IBM, Merck on new Rx program

BENTONVILLE, Ark. — IBM, KPMG, Merck and Walmart announced Thursday that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed

Merck and NGM Bio extend strategic collaboration to 2022

Merck and NGM Bio extend strategic collaboration to 2022

KENILWORTH, N.J. — Merck and NGM Biopharmaceuticals, Inc. (NGM) Wednesday announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022. The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across

Healthy Interactions and Merck launch digital health platform

Healthy Interactions and Merck launch digital health platform

KENILWORTH, N.J. — Healthy Interactions, a global leader in health education, in collaboration with Merck, known as MSD outside the United States and Canada, today announced the launch of map4health – a digital platform and mobile application in the U.S. that was designed to help facilitate and enhance communications between diabetes patients and educators. This technology was

Merck gets FDA Approval for GONAL-f prefilled pen

Merck gets FDA Approval for GONAL-f prefilled pen

DARMSTADT, Germany — Merck has received approval for a new version of GONAL-f (follitropin alfa injection) prefilled pen from the U.S. Food and Drug Administration (FDA). Known as GONAL-f RFF Redi-ject prefilled pen in the U.S. and originally approved by the FDA in 2013, the new version of the pen is easy-to-learn and easy-to-use. “Aspiring

Merck CEO’s tweet draws Trump counter-tweet

Merck CEO’s tweet draws Trump counter-tweet

Amid the shakeout from President Donald Trump’s statements on the violence erupting in protests in Charlottesville, Va., Merck & Co. chairman and CEO Kenneth Frazier said he’s leaving the President’s American Manufacturing Council. Frazier said in a statement posted on Twitter early Monday morning, “I am resigning from the President’s American Manufacturing Council. Our country’s

Merck names new head of manufacturing

Merck names new head of manufacturing

KENILWORTH, N.J. — Sanat Chattopadhyay has been promoted to executive vice president and president of the Merck Manufacturing Division (MMD). Plans call for Chattopadhyay, currently senior vice president of Global Manufacturing Operations (Human Health), to start in the new position on April 1. He succeeds Willie Deese who will retire on June 1 after 12 years

Merck OK’d for Gardasil 9 expanded age indication

Merck OK’d for Gardasil 9 expanded age indication

KENILWORTH, N.J. — Merck has received approval from the Food and Drug Administration for an expanded age indication for Gardasil 9, its 9-valent human papillomavirus (HPV) vaccine. The company said the new indication allows Gardasil 9 to include use in males ages 16 to 26 years for the prevention of anal cancer caused by HPV